SCORE

39

NVIV: Invivo Therapeutics Holdings is a Sell


The current rating for NVIV is 39, which is 28% below its historic median rating of 50. This indicates higher risk than normal.


The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.